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Background: Hepatitis C virus (HCV) is common in men who have sex with men (MSM) with HIV. The Swiss HCVree 
Trial targeted a micro-elimination by using a treat and counsel strategy. Self-reported condom less anal intercourse with 
non-steady partners was used as the selection criterion for participation in a counselling intervention designed to 
prevent HCV re-infection. The purpose of this study was to assess the ability of this criterion to identify men who 
engaged in other sexual risk behaviours associated with HCV re-infection. 
Methods: Men who disclosed their sexual and drug- use behaviours during the prior 6 months, at study baseline, 
were included in the current study. Using a descriptive comparative study design, we explored self-reported sexual and 
drug-use risk behaviours, compared the odds of reporting each behaviour in men who reported and denied 
condomless anal intercourse with non-steady partners during the prior year and calculated the sensitivity/ 
specificity (95% Cl) of the screening question in relation to the other at-risk behaviours. 
Results: Seventy-two (61%) of the 118 men meeting eligibity criteria reported condomless anal intercourse 
with non-steady partners during the prior year. Many also engaged in other potential HCV transmission risk 
behaviours, e.g., 52 (44%) had used drugs. In participants disclosing drug use, 44 (37%) reported sexualised 
drug use and 17 (14%) injected drugs. Unadjusted odds ratios (95% Cl) for two well-known risk behaviours 
were 2.02 (0.80, 5.62) for fisting and 5.66 (1.49, 37.12) for injecting drug use. The odds ratio for sexualised drug use - a 
potential mediator for increased sexual risk taking - was 5.90 (2.44, 16.05). Condomless anal intercourse with non-steady 
partners showed varying sensitivity in relation to the other risk behaviours examined (66.7-88.2%). 
Conclusions: Although condom less anal intercourse with non-steady partners was fairly sensitive in detecting other 
HCV relevant risk behaviours, using it as the only screening criterion could lead to missing a proportion of HIV-positive 
men at risk for HCV re-infection due to other behaviours. This work also points to the importance of providing access 
to behavioral interventions addressing other sexual and drug use practices as part of HCV treatment. 
Trial registration: Clinical Trial Number: NCT02785666, 30.05.2016. 
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Background 
In men who have sex with men (MSM) living with HIV, 
co-infection with hepatitis C virus (HCV) has become a 
concern over the last 20 years [l ]. An HCV RNA-
screening of MSM with HIV (n = 3722) participating in 
the Swiss HIV Cohort Study (SHCS) between October 
2015 and May 2016 showed a prevalence of 4.8% (n = 
177) [2]. People living with an HIV/HCV co-infection 
show faster progression of liver fibrosis compared to 
people with HCV mono-infection and higher risk for 
liver-related morbidity and mortality [3]. Since the intro-
duction of the new direct acting antivirals (DAAs) cure 
is possible in 95% of the cases, making micro-
elimination of HCV a realistic target [4]. However, the 
population of MSM with HIV frequently present with 
HCV (re-) infections and current evidence shows that 
sexual transmission is one important source of (re-) in-
fection [ 5]. Addressing sexual risk behaviour should 
become an essential component of HCV medical treat-
ment [6]. 
In MSM, several sexual behaviours have been de-
scribed as potentially risky, for example mucosally trau-
matic sexual behaviours including condomless anal 
intercourse (CAI), receptive fisting, rectal bleeding, anal 
douching, sharing of sex toys and group sex activities; 
nasally applied drugs; injection drug use and drug use in 
combination with sex [7- 9]. Still, to-date, it remains 
controversial which risk behaviours are the most import-
ant ones regarding HCV transmission in MSM with 
HIV, and should subsequently constitute the most im-
portant targets for preventive efforts [10]. 
From 2015 to 2017, the Swiss HCVree Trial was con-
ducted as an investigator-initiated substudy of the SHCS 
using a test, treat and counsel strategy with the goal to 
eliminate HCV in the MSM population with HIV [ll]. 
An E-health assisted behavioural counselling interven-
tion with nurses as counselors was developed and imple-
mented with the aim to reduce sexual risk taking. MSM 
co-infected with HIV/HCV were asked to participate in 
the counseling intervention if they reported condomless 
anal intercourse with non-steady partners (nsCAI) the 
year prior to starting treatment [ll]. Condomless anal 
intercourse was the only risk behaviour for which SHCS 
data was available [12] at the time of intervention devel-
opment. However, its usefulness in selecting participants 
for the additional sexual risk reduction intervention re-
mains questionable given that other sexual and drug-
using behaviours are also important risk factors for HCV 
transmission. The current analysis was conducted to 
investigate the usefulness of nsCAI as the selection cri-
terion for the behavioural intervention. This can provide 
important information for further studies. Specifically, 
the aims of this study were to (1) describe sexual and 
drug-using behaviours participants reported during Swiss 
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HCVree study baseline assessment and to compare those 
behaviours in MSM who did and did not report nsCAI 
during the prior year and to (2) examine the condom-use 
question's sensitivity and specificity in identifying men 
who engaged in other HCV relevant risk behaviours and 
who may, therefore, also benefit from risk reduction 
interventions. 
Methods 
A descriptive comparative study design was used to 
address the objectives and included a comprehensive as-
sessment of social, medical and behavioural factors. Data 
were compared for differences between the two groups: 
those who reported nsCAI and those who denied nsCAI 
during the prior year. 
Setting and participants 
The Swiss HCVree Trial was implemented within the 
framework of the SHCS, an ongoing multicentre 
prospective observational study that started in 1988. Its 
participants have been shown to be highly representative 
of all known people living with HIV (PL WH) in 
Switzerland, [13] and modelling studies estimate that 
84% of all MSM with HIV in Switzerland are followed in 
the SHCS [14]. During the Swiss HCVree Trial (2015-
2017), all adult men with self-identified homosexual or 
bisexual preferences enrolled in the SHCS (n = 3722) 
were assessed for HCV ribonucleic acid (RNA) [2]. One 
hundered twenty-two (122) were diagnosed with HCV 
and treated with DAAs in one of eight specialized HIV 
clinics in Switzerland [ll] and all but one individual 
were cured. Among the men treated with DAAs, a posi-
tive response to the nsCAI question in the SHCS during 
the prior year was used to select men who were invited 
to participate in the sexual risk reduction intervention 
performed by nurses. 
Data collection 
The data used in this analysis were retrieved from the 
SHCS database and the Swiss HCVree Trial baseline 
assessment. Data included sociodemographic character-
istics (age, ethnicity/race, highest completed educational 
degree) and medical information about HIV from the 
SHCS database and HCV specific information from the 
Swiss HCVree Trial. At Swiss HCVree Trial baseline, 
participants were asked to complete a self-reported 
questionnaire about sexual and drug-use behaviours dur-
ing the previous 6 months. Table 1 summarizes the data 
collected. 
Data analysis 
Analyses were conducted using the open source R statis-
tical analysis software (Version 1.0.136 for Mac OS X). 
Participants' characteristics and self-reported at-risk 
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Table 1 Data collected 
Database Domain Variables assessed Question Answer 
Screening question SHCS, reported in 
interview situation 
Selection criteria for sexual "Over the last 12 months, did you have Yes/no 
risk reduction intervention unprotected anal intercourse with occasional 
partners?" 
Swiss HCVree Trial, Self-
completed 
questionnaires 
Sociodemographic 
Partnership "Did you have a stable partnership in the last 6 
months?" 
Yes/no 
Risk Behaviours 
Sextoys "Over the last 6 months, did you use sextoys with Yes/no 
non-steady partners?" 
Fisting 
Drug use 
"Over the last 6 months, did you practice fisting?" Yes/no 
"Did you use one or more of the following 
substances in the last 6 months?" 
Cocaine 
y-butyrolactone/y-hydroxybutyric acid (GHB/GBL) 
crystal methamphetamine (CM) 
Yes/no 
Yes/no 
Yes/no 
Yes/no 
Yes/no 
ketamine 
mephedrone 
"If your answer is yes, how did you take the 
substance(s)?" 
injection (slammed)/ intranasal/orally/ 
smoked/ mucosally (anal) 
Sexualised drug use "If your answer is yes, did you take any of the 
above-mentioned substance(s) in combination 
with sex?" 
Yes/no 
Psychological constructs 
Attitudes towards 
condom use 
Sexual risks scale-attitudes toward condom use 
[15] 13 items rated on a 5-point Like rt scale 
1 (I don't agree at all) to 5 (I completely 
agree). Possible scores range from 13 to 
65 
Condom self-efficacy Self-efficacy for negotiating condom use [16], 5 
items rated on a 1-1 O scale 
0 (I cannot) to 10 (I am sure that I can). 
Possible scores range from O to 50 
sexual and drug-use behaviours were analysed descrip-
tively. Depending on the level of measurement and dis-
tribution of variables, frequencies, percentages, means 
and standard deviations (SD), or median and interquar-
tile range (IQR) were calculated. Based on the SHCS 
data, participants were divided into two groups: those 
who reported no sex with non-steady partners or only 
protected anal intercourse during all sexual encounters 
during the last 12 months (i.e. without nsCAI) and those 
reporting nsCAI. Baseline characteristics, attitudes and 
self-efficacy regarding condom use were compared in 
the two nsCAI groups. Chi-square tests were used to 
compare categorical variables and the student's t-test 
(for age, which was normally distributed) or Mann-
Whitney U tests (for years since HIV diagnosis and 
scores on the attitudes toward condom use and self-
efficacy questionnaires, which were not normally distrib-
uted) were utilised to compare continuous variables. 
Odds ratios and their 95% confidence intervals (CI) were 
calculated to examine the association between nsCAI 
and the other risk behaviours assessed. Multivariable 
logistic regression was conducted to determine if adjust-
ing for age and duration of HCV affected the relation-
ship between nsCAI and the other risk behaviors. We 
used a manual stepwise backward elimination. MedCalc 
online software (https:/ /www.medcalc.org/calc/diagnostic_ 
test.php) was used to calculate the sensitivity and specificity 
(including 95% Cl) of the condom use screening question 
with non-steady sexual partners in relation to the 
other at-risk sexual and drug use behaviours. 
Results 
During the Swiss HCVree Trial baseline assessment, 118 
of 122 participants disclosed their sexual and drug-use 
behaviours and were included in the current study, see 
Fig. 1. 
Based on SHCS data, 72 (61%) MSM reported nsCAI 
and 46 (39%) reported no nsCAI during the 12 months 
prior to enrollment in the Swiss HCVree Trial. There 
were no significant differences in the two groups' socio-
demographic characteristics. There were significant group 
differences in the years since HCV diagnosis; MSM with 
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MSM with HIV screened for hepatitis C co-
infection included in the Swiss HIV Cohort 
Study 
(n=3722) 
I 
MSM with HIV and with replicating 
hepatitis C virus in the Swiss HCVree Trial 
(n=177 (4.8%)) 
I MSM with HIV/HGV but not treated in the Swiss 
I HCVree Trial 
(n =55) 
MSM with HIV/HGV receiving HGV treatment in (spontaneous clearance 3, death 1, treated 
outside study 38, replicating but not treated 13) the Swiss HCVree Trial and study acceptance 
(n=122) 
I MSM with HIV/HGV but no behavioural data 
I at baseline (n=4) 
I I 
MSM with HIV/HGV reporting consistent MSM with HIV/HGV reporting inconsistent 
condom use with non-steady-partners condom use with non-steady-partners 
at baseline of the Swiss HCVree Trial at baseline of the Swiss HCVree Trial 
MSM without nsCAI MSM with nsCAI 
(n=46) (n=72) 
Fig. 1 Flowchart Swiss HCVree Trial and group building according to men's response to the nsCAI screening question 
nsCAI had a shorter median duration of 1.9 years (0.9-
5.1) compared to MSM without nsCAI with a median 
duration of 4.8 years (2.1-10.3). Participants without 
nsCAI scored significantly more positive attitudes toward 
condom use and had higher self-efficacy related to con-
dom use than men with nsCAI (median score = 44.00 vs. 
39.00, p = .023 and median score= 40.72 vs. 29.23, p < .001 
respectively). 
Many men reported engaging in a variety of sexual 
or drug-use behaviours identified as risk factors for 
HCV-infection: 25 (24%) shared sextoys, 28 (25%) 
practised fisting and 52 (44%) used drugs during the 
prior 6 months. In participants who answered the 
drug-use questions, 44 (37%) reported sexualised drug 
use and 17 (15%) injected drugs. Participants reported 
using the following drugs: 30 (26%) used y-
butyrolactone/y-hydroxybutyric acid (GHB/GBL), 26 
(22%) cocaine, 22 (19%) crystal methamphetamine, 11 
(9%) ketamine and 10 (9%) mephedrone (Table 2). 
Those with nsCAI during the 12 months prior to 
treatment were more likely to have engaged in other 
risky sexual behaviours than those without nsCAI al-
though the odds in the two groups were only statisti-
cally significant for drug use, drug use during sex and 
injecting drugs. Adjusting for age and/or HCV dur-
ation did not change the relationship between nsCAI 
and the other risk behaviours examined in terms of 
the direction or significance of the odds ratios. 
Odds ratios for two sexual behaviours with established 
transmission risk were 2.02 (0.80, 5.62) for fisting and 
5.66 (1.49, 37.12) for injecting drug use. Sexualised drug 
use, a potential mediator for increasing other risk behav-
iours, showed an odds ratio of 5.90 (2.44, 16.05), see 
Table 2. 
Table 3 summarizes the results of analyses examining 
the sensitivity and specificity of reporting consistent 
condom-use with non-steady partners at study baseline 
in identifying men who did not engage in the other at-
risk behaviours examined. The nsCAI question had the 
highest sensitivity in relation to the question about 
injecting drugs (88.2%) and lowest for sharing sex toys 
(66.67%). Specificity was low in all analysed risk behav-
iours (41.18-57.58%). 
Discussion 
The MSM co-infected with HIV/HCV in this study prac-
ticed various sexual and drug use behaviours associated 
with HCV transmission risk in addition to condomless 
sex. While nsCAI was associated with higher odds of 
engaging in other behaviours, based on our findings, 
relying only on this question to identify men at risk for 
HCV re-infection is likely miss a proportion of MSM 
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Table 2 Sociodemographic and HCV-related risk behaviours in the last 6 months at study baseline 
Sociodemographic and Total Participants Participants with nsCAI Univariable Odds Ratio Multivariable Adjusted Adjusted OR 
HCV-related risk behaviours (n= 118) without nsCAI (n=72) (95% Cl) OR (95% Cl) for age (95% Cl) for 
at study baseline (n=46) and HCV duration HCV duration 
Age, mean (sd) 46.6 (+/- 49.0 (+/- 9.1) 45.1 (+/-9.1) 0.64 (0.41, 0.96)° 
9.2) 
HCV duration, median 2.9 (1.1- 4.8 (2. 1-10.3) 1.9 (0.9-5.1) 0.87 (0.80, 0.94) 
(IQR) 7.1) 
Sharing sextoys, n (%) 25 (24) 7 (18) 18 (28) 1.53 (0.58, 4.40) 1.05 (0.36, 3.21) 1.08 (0.37, 
(n = 104/38/66)b 3.29) 
Fisting, n (%) (n = 114/ 28 (25) 7 (16) 21 (30) 2.02 (0.80, 5.62) 2.12 (0.78, 6.31) 1.92 (0.72, 
43/71)b 5.60) 
Drug use, n (%) (n = 117/ 52 (44) 8 (18) 44 (61) 7.27 (3.08, 18.91) 5.58 (2.26, 15.02) 5.79 (2.37, 
45/72)b 15.42) 
GHB/GBL, n (%) 30 (26) 3 (7) 27 (38) 8.60 (2.78, 37.87) 6.64 (2.04, 30.18) 6.91 (2.15, 
31.07) 
Cocaine, n (%) 26 (22) 6 (13) 20 (28) 2.56 (0.99, 7.55) 2.36 (0.85, 7.39) 2.49 (0.91, 7.6) 
Crystal methamphetamine, 22 (19) 1 (2) 21 (29) 18.48 (3.63, 338.0) 15.47 (2.89, 288.31) 15.91 (3.01, 
n %) 294.78) 
Ketamine, n (%) 11 (9) 2 (4) 9 (14) 3.12 (0.76, 21.14) 3.55 (7.82, 25.71) 3.55 (7.82, 
25.71) 
Mephedrone, n (%) 10 (9) 10 (15) 
Use of any of the drugs 44 (38) 7 (16) 37 (52) 5.90 (2.44, 16.05) 4.42 (1.73, 12.52) 4.63 (1.84, 
listed above during sex, n 12.92) 
(%) (n = 116/45/71 )b 
Reporting injection of 17 (15) 2 (4) 15 (21) 5.66 (1.49, 37.12) 4.45 (1.10, 30.15) 4.53 (1.13, 
drugs, n (%) (n = l l 7 /45/72)b 30.51) 
•unit 1 o years 
bspecified how many HIV-positive MSM answered the question (n = total group/without nsCAl/with nsCAI) 
with HIV at risk for HCV due to other behaviours. 
Between 16 to 18% of the men who denied nsCAI 
reported engaging in other behaviors that have been 
associated with an increased risk of HCV re-infection. 
Eighteen percent (18%) of those who denied nsCAI 
reported using drugs. This is an important finding as 
drug use is seen as a potential mediator for increased 
sexual risk-taking [17, 18]. 
Condom use was the only risk behaviour available for 
all men in the SHCS and was for this reason used as the 
criterion for selecting men to participate in the sexual 
risk reduction behavioural intervention portion of the 
Table 3 Sensitivity analysis of screening question "nsCAI" to 
identify other probable risk behaviours for HCV re-infection 
Risk Behaviours Sensitivity" (%) (95% Cl) Specificitl (%) (95% Cl) 
Any drug use 84.62 (71.92-93.12) 57.58 (44.79-69.66) 
Sexualised drug use 84.09 (69.93-93.36) 52.70 (40.75-64.43) 
Injecting drug use 88.24 (63.56-98.54) 43.56 (33.72-53.80) 
Fisting 75.00 (55.13-89.31) 43.18 (32.66-54.18) 
Sharing of sex toys 66.67 (48.17-82.04) 41.18 (30.61-52.38) 
"The probability that HIV-positive MSM report a selected risk behaviour will 
also report nsCAI 
t>i"he probability that HIV-positive MSM will deny nsCAI if they are not 
engaging in other selected other risk behaviours 
Swiss HCVree Trial [19]. Despite our use of this inclu-
sion criterion, its discriminatory value in identifying men 
at high risk for HCV re-infection was unclear. However, 
a recent study from London found that CAI was a 
significant risk factor for acute HCV infection in MSM 
and in one third of participants it was the only risk 
factor [9]. In contrast to our study, MSM received care 
in a sexual health clinic and benefitted from a multi-
disciplinary prevention approach including harm reduc-
tion services whereas in our study, HCV treatment was 
given in specialised medical HIV clinics. In line with 
other investigations in MSM with HIV, study partici-
pants reported various behaviours other than nsCAI that 
potentially increased their risk of HCV sexual transmis-
sion [9]. It has been well documented that condoms are 
less attractive in the MSM community - largely due to 
the common understanding and awareness that HIV 
treatment is preventive in terms of HIV transmission 
[20]. Decreasing trends of condom use was confirmed in 
a systematic review of studies across high-income coun-
tries [21]. Champenois et al. [22] reported that for MSM 
with HIV the main reasons for not using condoms were 
serosorting and being on antiretroviral therapy (ART) 
with undetectable viral loads. While these traditional 
HIV-related risk reduction strategies (serosorting and 
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effective HIV treatment) have been shown to prevent 
the transmission of HIV, they have little or no effect in 
preventing HCV or other sexually transmitted diseases. 
In our study, MSM with HIV and nsCAI were more 
likely to engage in other risk behaviours compared to 
those without nsCAI but the relationship was only statis-
tically significant for drug-use and sexualized drug-use. 
However, due to the small sample size, our study was 
probably only adequately powered to detect large differ-
ences in the groups. They were two-times more likely to 
practice fisting and six times more likely to report sexua-
lised drug use. The sensitivity of the nsCAI question was 
85% in relation to drug use. Nevertheless, our findings 
indicate that using nsCAI as the only risk behaviour 
criterion to select men for the behavioural intervention 
was likely to have resulted in failure to include between 
12 and 34% of those engaging in other risk behaviours. 
Each single behaviour included in the current analysis 
carries a specific HCV transmission risk; however, which 
behaviour or combinations of behaviours carry the high-
est risks is currently less clear and cannot be answered 
with this study design. 
Our results are in line with other studies showing as-
sociations between higher rates of drug use/sexualised 
drug use and risk behaviors [18, 23, 24]. A substantial 
proportion of our participants reported drug use (44%). 
Among the men who answered these questions (116 for 
sexualized drug use and 117 for injecting drugs), 38% 
reported sexualised drug use and 15% reported injecting 
substances. In comparison, in two earlier studies on 
MSM with HIV- one from Madrid (n = 742) [23] and 
one from England/Wales (n = 392) [24]- 29.1-29.5% of 
participants indicated sexualised drug use and 10.1-16% 
injecting drug use. Our group's higher rate of sexualised 
drug use might reflect differences in the study popula-
tion, especially the fact that our sample's MSM with 
HIV were all co-infected with HCV. Several studies have 
found elevated rates of sexualised drug use in MSM co-
infected with HIV/HCV, affirming associations between 
sexual HCV transmission and higher risk taking behav-
iours when using substances [25, 26]. Another possible 
explanation for our group's high rates of sexualised drug 
use may be related to the study setting: most of our par-
ticipants were recruited at the centres in Zurich, a town 
known for a comparably high prevalence of sexualised 
drug use. In the European MSM Internet Survey (EMIS-
2010), which compared 44 European cities in relation to 
illicit drug use in MSM, place of residence was the 
strongest predictor. Zurich reported a 7% prevalence of 
using one of the four drugs typically used during sex, 
ranking sixth of the 44 cities studied, just after UK and 
Spanish cities [8]. In another European survey conducted 
among MSM in 13 cities, overall prevalence of sex asso-
ciated with drug use was 11.8% (when measured at the 
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last sexual encounter), and was more frequently reported 
by MSM with HIV [27]. 
The four substances typically used during sex were all 
reported in our study, with GBL/GHB being the most 
common (25%), followed by crystal methamphetamine 
(19%). In EMIS (European MSM Internet Survey), per-
centages of GBL/GHB use were quite similar, but crystal 
methamphetamine use was lower [8] than in our study, 
suggesting a surge in its popularity in MSM with HIV. 
The frequency of cocaine use was also high (22%) -
comparable to rates reported in the UK ASTRA trial in 
MSM with HIV or for Zurich in EMIS [8, 18]. To date, 
few studies investigating sexualized drug use have in-
cluded cocaine. However, our results indicate that cocaine 
may be more common (19%) in sexual contexts than 
expected. 
This study has several limitations. The study's cross-
sectional design precluded any causal inferences about 
the associations between nsCAI and other behaviours 
risky for HCV re-infection. During analysis, we identified 
some limitations in the formulation of questions, e.g., we 
did not ask about the distinction between insertive or re-
ceptive fisting. While self-report questionnaire data may 
be biased, especially for such sensitive domains as sexual 
and drug use behaviour, it is often perceived as superior 
compared to being asked by someone else because of 
reduced social desirability bias [28]. Given the limited 
number of MSM co-infected with HIV/HCV in 
Switzerland, the study sample (118 participants) was 
small. The small sample size may have limited our ability 
to detect statistically significant differences in behaviors 
in the nsCAI and non-nsCAI groups that were clinically 
meaningful. One strength of the study is that Swiss 
HCVree Trial (the source of data for this study) 
screened and treated all participants co-infected with 
HCV in the SHCS, so the sample is likely to be represen-
tative of MSM with HIV living in Switzerland [13]. 
Conclusions 
Our findings support existing research that MSM co-
infected with HIV/HCV engage in various sexual and 
drug-use behaviours, potentially increasing their risk of 
HCV re-infection. Men who reported using condoms 
inconsistently with non-steady partners were more likely 
to report engaging in the other sexual and drug-use 
behaviors measured although the differences were only 
statistically significant for the drug-use behaviors. nsCAI 
was fairly sensitive in identifying men who also engaged 
in other risk behaviours, but relying only on it to identify 
men at risk for HCV infection would miss a proportion 
of MSM with HIV practicing other potentially modifi-
able behaviours. Based on our findings we recommend 
comprehensive screening of potential risk behaviours to 
identify men whose sexual and drug use behaviors 
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increase their risk for HCV infection. We recommend 
offering all MSM co-infected with HIV/HCV behav-
ioural interventions designed to reduce sexual and drug 
use risk behaviours. 
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